uploads///Graph

BMY and Celgene to Form a Leading Global BioPharma Company

By

Jan. 8 2019, Updated 9:01 a.m. ET

Immuno-oncology opportunities

According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both the solid tumor and hematologic malignancy segments after completing the acquisition of Celgene (CELG). The company expects Opdivo, Yervoy, Revlimid, and Pomalyst to be the key growth drivers of its oncology portfolio in the future.

According to Bristol-Myers Squibb’s M&A conference transcript, Bristol-Myers Squibb has already managed to reach up to $7.5 billion of annualized revenues from the sale of its immuno-oncology products. The company has also secured more regulatory approvals in more than 17 indications in the US market and more than 400 approvals across the world for Opdivo.

Article continues below advertisement

Other franchises

According to the company’s investor presentation, Bristol-Myers Squibb expects its combination with Celgene to also create one of the leading immunology and inflammation franchises driven by Otezla and Orencia. Finally, according to the company’s investor presentation, the combined company is expected to be a top-ranking cardiovascular player led by Eliquis.

In addition to a robust commercial portfolio, the combined company is also expected to have a solid early as well as late-stage research pipeline. According to the company’s investor presentation, Bristol-Myers Squibb will be launching six new products in the next one to two years after the completion of the acquisition of Celgene. Additionally, the combined company will have ten phase 3 programs and multiple label expansion programs for commercialized products in its late-stage research pipeline.

According to the company’s investor presentation, Bristol-Myers Squibb also expects to create a robust early and mid-stage research pipeline with 21 immuno-oncology assets in solid tumor indications, ten oncology assets in the hematology indication, nine assets in cardiovascular and fibrosis indications, and ten immunology and inflammation assets.

In the next article, we’ll discuss growth drivers for Bristol-Myers Squibb’s oncology business in greater detail.

Advertisement

More From Market Realist

  • Businesswoman looking out a window
    Company & Industry Overviews
    Shifting Focus: Three Women Investing Funds in 2021
  • Aol logo on office building,
    Company & Industry Overviews
    What We Know About Apollo Global Management, New Owners of AOL and Yahoo
  • Chick-fil-A sign
    Company & Industry Overviews
    Why It Only Costs $10K to Own a Chick-fil-A Location
  • Beyond Meat Burger 3.0
    Company & Industry Overviews
    How Is Beyond Burger 3.0 Different and Will It Bring BYND Stock Up?
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.